Revolution Medicines Inc (RVMD)

Apr 02, 2025

When the Price of (RVMD) Talks, People Listen - news.stocktradersdaily.com

Apr 02, 2025

Apr 01, 2025

Revolution Medicines to Deliver Multiple Presentations at - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan

Apr 01, 2025

Mar 31, 2025

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - MSN

Mar 31, 2025

Mar 31, 2025

Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan

Mar 31, 2025

Mar 31, 2025

Revolution Medicines to Participate in April 2025 Investor Conferences - The Manila Times

Mar 31, 2025

Mar 31, 2025

RVMDRevolution Medicines, Inc. Latest Stock News & Market Updates - Stock Titan

Mar 31, 2025

Mar 30, 2025

Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey

Mar 30, 2025

Mar 24, 2025

Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com

Mar 24, 2025

Mar 20, 2025

Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 19, 2025

Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 19, 2025

Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada

Mar 19, 2025

Mar 19, 2025

Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India

Mar 19, 2025

Mar 19, 2025

Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com

Mar 19, 2025

Mar 19, 2025

Revolution Medicines Executives Sell Shares - TradingView

Mar 19, 2025

Mar 19, 2025

Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock - Investing.com

Mar 19, 2025

Mar 15, 2025

Revolution Medicines Inc (RVMD) Should Be Considered For The Next Few Weeks - Stocks Register

Mar 15, 2025

Mar 13, 2025

Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 20 - GuruFocus.com

Mar 13, 2025

Mar 13, 2025

Revolution Medicines at Leerink Conference: Expanding RAS Inhibitor Reach By Investing.com - Investing.com Canada

Mar 13, 2025

Mar 12, 2025

Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com Canada

Mar 12, 2025

Mar 12, 2025

Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Revolution Medicines at Barclays Conference: Focus on Pancreatic Cancer Trials - Investing.com UK

Mar 11, 2025

Mar 06, 2025

Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey

Mar 06, 2025

Mar 04, 2025

10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey

Mar 04, 2025

Mar 04, 2025

Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs - TipRanks

Mar 04, 2025

Mar 04, 2025

HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - Defense World

Mar 04, 2025

Mar 03, 2025

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance

Mar 03, 2025

Mar 03, 2025

10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey

Mar 03, 2025

Mar 02, 2025

Revolution Medicines’ (RVMD) “Outperform” Rating Reiterated at Wedbush - Armenian Reporter

Mar 02, 2025

Mar 01, 2025

Long Term Trading Analysis for (RVMD) - Stock Traders Daily

Mar 01, 2025

Mar 01, 2025

Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD) - Defense World

Mar 01, 2025

Feb 28, 2025

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com

Feb 28, 2025

Feb 27, 2025

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com

Feb 27, 2025

Feb 27, 2025

Revolution stock price target cut to $59 at Needham - Investing.com

Feb 27, 2025

Feb 27, 2025

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Feb 27, 2025

Feb 27, 2025

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Feb 27, 2025

Feb 26, 2025

Revolution Medicines Reports 2024 Financial Results and Progress - TipRanks

Feb 26, 2025

Feb 26, 2025

Earnings call transcript: Revolution Medicines Q4 2024 reflects strategic advancements - Investing.com India

Feb 26, 2025

Feb 26, 2025

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress - GlobeNewswire

Feb 26, 2025

Feb 26, 2025

Revolution Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025

Feb 26, 2025

Revolution Medicines Q4 Net Loss Narrows -February 26, 2025 at 05:13 pm EST - Marketscreener.com

Feb 26, 2025

Feb 26, 2025

Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99 - Marketscreener.com

Feb 26, 2025

Feb 26, 2025

Revolution Medicines, Inc. SEC 10-K Report - TradingView

Feb 26, 2025

Feb 26, 2025

Can Revolution Medicines' $2.3B War Chest Overcome Mounting Losses in Cancer Drug Race? - StockTitan

Feb 26, 2025

Feb 25, 2025

Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 2024 Result - Yahoo Finance

Feb 25, 2025

Feb 24, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences - The Manila Times

Feb 24, 2025